Emergent BioSolutions (EBS) Tax Provisions (2011 - 2026)

Emergent BioSolutions' Tax Provisions history runs 16 years deep, the most recent figure standing at $6.6 million for Q1 2026.

• On a quarterly basis, Tax Provisions fell 73.28% year-over-year to $6.6 million in Q1 2026; TTM through Mar 2026 was $12.1 million, a 82.54% decrease from a year earlier, with the FY2025 full-year figure at $30.2 million, down 36.69% from the prior year.
• Tax Provisions climbed to $6.6 million in Q1 2026 per EBS's latest filing, from $3.9 million in the prior quarter.
• Across five years, Tax Provisions topped out at $27.6 million in Q3 2024 and bottomed at -$26.4 million in Q2 2022.
• The 5-year median for Tax Provisions is $5.6 million (2022), against an average of $6.6 million.
• Across the five-year window, Tax Provisions slumped 1115.38% in 2022 and soared 25700.0% in 2023, its largest moves.
• Year by year, Tax Provisions stood at $5.6 million in 2022, then tumbled by 189.29% to -$5.0 million in 2023, then jumped by 174.0% to $3.7 million in 2024, then gained by 5.41% to $3.9 million in 2025, then surged by 69.23% to $6.6 million in 2026.
• Per Business Quant, the three latest EBS Tax Provisions figures stand at $6.6 million (Q1 2026), $3.9 million (Q4 2025), and $6.4 million (Q3 2025).